(19)
(11) EP 4 228 617 A1

(12)

(43) Date of publication:
23.08.2023 Bulletin 2023/34

(21) Application number: 21795012.0

(22) Date of filing: 14.10.2021
(51) International Patent Classification (IPC): 
A61K 31/14(2006.01)
A61K 9/107(2006.01)
A61P 27/02(2006.01)
 A61K 9/00(2006.01)
A61K 9/127(2006.01)
A61P 31/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/14; A61K 9/0048; A61P 27/02; A61P 31/14; A61K 9/08
(86) International application number:
PCT/IB2021/059468
(87) International publication number:
WO 2022/079664 (21.04.2022 Gazette 2022/16)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 15.10.2020 US 202063092399 P
04.05.2021 US 202163183928 P
28.07.2021 US 202163226614 P

(71) Applicant: Bausch + Lomb Ireland Limited
Dublin (IE)

(72) Inventors:
  • MCCORMICK, Patrick
    Rochester, New York 14609 (US)
  • MILLARD, Kimberly
    Rochester, New York 14609 (US)

(74) Representative: Finnegan Europe LLP 
1 London Bridge
London SE1 9BG
London SE1 9BG (GB)

   


(54) BENZALKONIUM CHLORIDE FOR USE IN TREATING CONJUNCTIVITIS AND/OR COVID-19